Scribd Logo
Upload

Welcome to Scribd!

  • RCT Stem Cell Research in Animals and Humans

    Uploaded by

    enricvcf
    12 views16 pages
    Cell Therapy therapeutic dose BM or AT harvest 10 days cellular pre plating crio preserved intermediate product expantion cells muscle repair timing inflammation degeneration regeneration Time Factor fibrosis 3w dose Factor.

    Original Description:

    Original Title

    muscletech2013solerorozco-131015074821-phpapp02.pdf

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Cell Therapy therapeutic dose BM or AT harvest 10 days cellular pre plating crio preserved intermediate product expantion cells muscle repair timing inflammation degeneration regeneration Time Factor fibrosis 3w dose Factor.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    12 views16 pages

    RCT Stem Cell Research in Animals and Humans

    Uploaded by

    enricvcf
    Cell Therapy therapeutic dose BM or AT harvest 10 days cellular pre plating crio preserved intermediate product expantion cells muscle repair timing inflammation degeneration regeneration Time Factor fibrosis 3w dose Factor.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 16

    RCT

    in stem cells

    From theory to prac4ce


    HOSPITAL CLNIC VETERINARI

    Equine CARTILAGE

    animal model

    Ovine CARTILAGE
    Ovine P. NERVE
    Equine tendon

    BONE

    Maxilar

    Aastrom

    Pseudoarthrosis Aastrom

    BST

    Pseudoarthrosis Aastrom

    BST

    Osteonecrosis

    clinical trials

    BST

    BST

    Aastrom

    Pseudoarthrosis Salvat - Histocell

    DISC

    CARTILAGE

    IBGM

    PEi 10-134
    OA II-III

    BST

    OA II-IV

    IBGM

    OA II-IV crio

    MSC RESEARCH 2013

    PEi 10-005

    IBGM

    OA II-IV alo vs hialur.


    OA II-IV (MSC vs PRP)

    PEi 05-048

    IBGM

    PEi

    EMA

    Ensayo clnico III Uso Compasivo

    Procedimiento
    Centralizado

    Clusula
    Exclusin

    Ensayo clnico I-II

    PEi
    RD 1301/2006 RD1825/2009

    OCATT

    ONT

    Hospital
    RD 2043/94
    RD 1369/2000

    preclnica BPL

    AEMPS

    CEICs
    Gestora

    CRO
    protocolo

    inves4gadores
    Financiacin

    RD 223/2004
    Ley 29/2006
    RD 1344/2007
    Ley 14/2007

    Laboratorio GMP
    Promotor

    Advanced Therapy
    characterized
    accurate dose
    presentation
    Medicines Agency control

    phenotype
    immunophenotype

    plastic adherence
    presentation

    pluripotency
    ro
    t
    i
    v
    in

    MS
    C
    dexametasona
    TGF-
    glucocorticoides
    indometacina
    cido
    ascrbico
    5%
    suero
    equino
    isobutilmetilxilina

    osteocito
    condrocito
    miocito
    c. estroma
    tenocito
    adipocito
    Osiris Therapeutics

    muscle repair timing


    inflammation
    degeneration regeneration

    1w

    2w

    Time Factor
    fibrosis

    3w
    Dose Factor

    RICES

    Cell
    Therapy
    therapeutic
    dose

    BM or AT harvest
    10 days

    cellular pre plating


    crio preserved
    intermediate product

    expantion cells

    RICES

    Cell
    Therapy
    therapeutic
    dose

    BM or AT allogenic
    10 days

    cellular pre plating


    crio preserved
    intermediate product

    expantion cells

    muscle repair timing


    inflammation
    degeneration regeneration

    1w

    2w

    Time Factor
    fibrosis

    3w
    Dose Factor

    o
    r
    t
    i
    in v

    MS
    C

    osteocito
    condrocito
    miocito
    c. estroma
    tenocito
    adipocito
    Osiris Therapeutics

    12 equinos
    lesin SDTF
    20x10E6 MSC

    BM-MSC 6
    AT-MSC 6
    SF

    prp

    manguito rotadores
    20x10E6 MSC + membrana
    Hospital Universitario San Carlos. Madrid

    epicondilitis
    1x10E6 vs 10x10E6 allo-AT MSC

    Conclusiones
    Terapia celular con MSC
    (dosis: 15x10E6 a 40x10E6)

    Viable
    Segura
    Indicios de eficacia
    Actual: Solo bajo ensayo o UC
    Control Agencia Medicamento


    RCT in stem cells

    From theory to prac4ce


    HOSPITAL CLNIC VETERINARI

    You might also like